MIAMI, Florida, United States – May 10, 2026
Longeveron announced details from a constructive Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the ongoing development of laromestrocel (LOMECEL-B®) for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect affecting infants. The discussions come ahead of the anticipated August 2026 topline data readout from the company’s randomized, controlled Phase 2b ELPIS II clinical trial. According to the company, the FDA acknowledged the severe unmet medical need associated with HLHS and expressed willingness to continue regulatory discussions following completion of the trial.
While the Agency indicated that the current primary endpoint of right ventricle ejection fraction (RVEF) would not be considered sufficient to establish efficacy, the FDA also confirmed that objective clinical outcomes such as all-cause mortality, transplant-free survival, cardiac transplantation events, and major adverse cardiac events (MACE) may provide meaningful evidence supporting future regulatory evaluation. The update represents a significant regulatory milestone as Longeveron continues positioning laromestrocel within the emerging regenerative medicine landscape for pediatric cardiovascular diseases.
FDA Feedback Shapes Potential Regulatory Pathway for Laromestrocel
Longeveron stated that the FDA no longer considers the ongoing ELPIS II study to be a pivotal trial because no new agreed-upon primary endpoint can be formally established while the study remains blinded and active. The challenge emerged following a previously mandated interim analysis conducted by the National Institutes of Health (NIH), which limited the ability to revise endpoints during the ongoing study. Nevertheless, company leadership emphasized that the FDA remained open to future discussions after final data become available, signaling a potentially flexible regulatory pathway depending on the overall clinical evidence package. Longeveron plans to submit a revised Sponsor Statistical Analysis Plan (SAP) incorporating composite primary and secondary endpoints for FDA review.
The company remains optimistic that the totality of evidence from ELPIS II, combined with existing safety and efficacy observations, could support a future Biologics License Application (BLA) submission. The laromestrocel program has already received multiple important FDA regulatory designations, including Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, highlighting the significant unmet medical need associated with HLHS and the FDA’s interest in accelerating innovative pediatric therapies.
Advertisement
ELPIS II Evaluates Stem Cell Therapy for Rare Pediatric Heart Disease
The ongoing ELPIS II trial is a multicenter, randomized, controlled Phase 2b clinical study evaluating laromestrocel as an adjunctive therapy in infants undergoing Stage II surgical palliation for HLHS. The study enrolled 40 pediatric patients across twelve leading children’s hospitals and cardiovascular treatment centers in the United States through collaboration with the National Heart, Lung, and Blood Institute (NHLBI) under NIH grant support. HLHS is one of the most severe congenital heart defects, characterized by an underdeveloped or missing left ventricle that severely compromises systemic blood circulation shortly after birth.
Infants diagnosed with HLHS typically require multiple staged reconstructive surgeries during the first several years of life, yet mortality rates remain high due to progressive right ventricular failure and long-term cardiac complications. Laromestrocel is an investigational allogeneic mesenchymal stem cell (MSC) therapy derived from healthy adult bone marrow donors and designed to provide regenerative, anti-inflammatory, vascular-supportive, and tissue repair effects. The therapy is being explored as a potential strategy to improve right ventricular function, reduce complications, and enhance survival outcomes in HLHS patients facing limited treatment options beyond surgical intervention.
Regenerative Medicine Expands in Pediatric Cardiovascular Disease
Longeveron’s regulatory progress reflects growing industry and investor interest in applying regenerative medicine technologies to pediatric cardiovascular disorders with few effective therapeutic options. Cell-based therapies targeting inflammation, tissue repair, and vascular remodeling are increasingly viewed as promising approaches for congenital and chronic heart diseases where conventional pharmacologic interventions provide limited long-term benefit.
Beyond HLHS, Longeveron is also advancing laromestrocel development programs in Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM), and aging-related frailty, further positioning the company within the broader regenerative medicine sector. As regulatory agencies continue refining frameworks for cell and gene therapies addressing rare diseases, successful outcomes from ELPIS II could potentially establish one of the first regenerative medicine approaches targeting pediatric congenital heart failure. The upcoming August 2026 topline data release is expected to become a closely watched milestone within both regenerative medicine and pediatric cardiology sectors as stakeholders assess laromestrocel’s future clinical and commercial potential.
Source: Longeveron press release
